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ABSTRACT  
 Sympathetic neural factors played an important role in homeostatic blood pressure 
control. Dysregulation in sympathetic function may favor the development and progression 
of the hypertensive state. Beta-blocker, as one of antihypertensive drugs, provides several 
positive effects to hinder overactivity of sympathetic nerve in patients with hypertension.  
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Introduction 
Autonomic nervous system has a 
pivotal role in modulating cardiovascular 
functions and in controlling blood pressure 
values, both at rest and in response to 
environmental stimuli. Hypertension, as 
one of most challenging condition, is 
considered induced by derangement of 
sympathetic and parasympathetic 
cardiovascular regulation. Appearance 
and sustained high blood pressure were 
maintained by enhanced sympathetic 
nerve activity and an attenuated vagal 
cardiac tone in animal models of 
hypertension.1  
 
Activity of sympathetic nervous  
system  
 Sympathetic nervous system 
(SNS) is responsible to control and to 
maintain various body conditions such as 
regulatory mechanism of blood pressure, 
electrolyte balance, and maintenance of 
homeostatic state. This system is also 
integral part in the regulation of daily 
energy expenditure through the control of 
resting metabolic rate and thermogenesis 
in response to various physiological 
stimuli, changing states of energy, intake 
of food, consumption of carbohydrate, and 
hyperinsulinemia. Therefore, SNS 
overactivation is steadily related with at 
least two component of metabolic 
syndrome, i.e hypertension and obesity.2 
 
Hyperactivity of SNS in many 
diseases  
In obese humans with the 
metabolic syndrome, muscle sympathetic 
nerve traffic values are augmented even 
without hypertension.3 Muscle sympathetic 
nerve activity is concordant with waist 
circumference in individuals with the 
metabolic syndrome.3 In addition, during 
diet-induced weight loss, the decreases in 
sympathetic activity are accompanied by 
reduction in all components of the 
metabolic syndrome.4 In other conditions, 
sympathetic activity is elevated in patients 
with mild to moderate or end-stage renal 
insufficiency.5,6 This condition was also 
found in obstructive sleep apnea and 
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chronic obstructive pulmonary diseases 
which lead to more predominance of 
sympathetic over parasympathetic activity 
in heart rate modulation.7  
 
Hyperactivity of SNS in 
hypertension 
One hypothesis stated "neurogenic 
nature of high blood pressure". It tried to 
explain that hypertensive state was 
affected by dysregulation in sympathetic 
modulation of cardiovascular function, 
mainly contributing in its early 
development and late progression.8  
Sympathetic role in cardiovascular 
system had repeatedly studied to clarify its 
part in the progression of essential 
hypertension. One study reported that 
juvenile hypertension was correlated with 
resting tachycardia, which has 
hyperkinetic state. This condition might be 
triggered by adrenergic overdrive, 
observed by increased main adrenergic 
neurotransmitter, i.e norepinephrine in 
young patients.9  Other study also showed 
that young-stage 1 hypertensive patients 
which has sympathetic predominance had 
sustained hypertension than those who 
were without autonomic nervous system 
dysfunction after six years of follow-up.10 
In addition, sympathetic activation 
reflected by higher resting heart rate, 
produce turbulent blood flow in vessels 
bifucartio, generate atherosclerotic 
plaque, and increase the stiffness of large 
blood vessels.11,12,13,14 Not only affecting in 
enhancing resting heart rate values, 
cardiac sympathetic drive is also 
associated with structural and functional 
modification of myocardial, such as left 
ventricular hypertrophy or left ventricular 
diastolic dysfunction, resulting in elevated 
morbidity and mortality if its left 
untreated.15,16,17  
Several mechanism that are 
proposed to explain mechanism of 
hypertension-related SNS overactivity 
including baroreflex dysfunction, 
cardiopulmonar reflex dysfunction, central 
factors, chemoreceptor activation, 
involvement of insulin/leptin, and renin-
angiotensin system and other 
humoralststems.1 In regard to baroreflex 
dysfunction, it is hypothesized that less 
response of baroreceptors to blood 
pressure changes due to cellular 
impairment or a stiffening of the arterial 
wall may trigger sympathetic overdrive. 
Eventhough, in one study, it showed that 
in hypertensive humans, the arterial 
baroreflex ability to control heart rate was 
weaken, it still continues to effectively 
modulate blood pressure and sympathetic 
activity.18 In addition, chemoreceptor 
stimulation by ischemic hypoxia was 
considered as a sympatostimulating factor 
in individuals with sleep apnea, a 
condition frequently associated with 
obesity and highly prevalent in 
hypertension.19   
Furthermore, studies from animal 
and human showed that insulin and leptin 
enhance postganglionic sympathetic 
drive20 and that central and peripheral 
sympathostimulating effects are also 
induced by angiotensin II.21 Most 
importantly, sympathetic nerve activity 
may be, either directly or indirectly, a 
predictor of CV morbidity and mortality. 
First, sympathetic activity is associated 
with and is probably a determinant of 
blood variability,22 which itself is a CV risk 
factor independent of average blood 
pressure values.23 Second, sympathetic 
hyperactivity, as measured by plasma 
norepinephrine, systemic norepinephrine 
spillover, or microneurography, is known 
to be an independent prognostic factor for 
CV-related morbid or fatal events in 
patients with heart failure, end-stage renal 
failure, major cardiac arrhythmias, 
obstructive pulmonary disease, or after an 
acute stroke.15,24,25,26 
 
Role of beta-blockers in 
hypertension 
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Since 1976, beta-blockers had 
been introduced for hypertension 
treatment. The various beta-blocking 
agents differ in terms of the presence or 
absence of intrinsic sympathomimetic 
activity (ISA), membrane stabilizing 
activity (MSA), β1-selectivity, α-adrenergic 
blocking activity, and relative potencies 
and duration of action.27  These drugs had 
proved effect to lower blood pressure and 
became recommended treatment option 
by the Joint National Committee on 
Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure.28 In 
addition, beta-blocking agents are 
considered to be an alternative first-line 
treatment for hypertension and are also 
indicated for patients having concomitant 
angina pectoris, arrhythmias, hypertropic 
cardiomyopathy, congestive 
cardiomyopathy, hyperdynamic 
circulations, essential tremor, or migraine 
headache.27  
Despite its various beneficial 
effect, recent evidence showed that 
starting therapy of hypertension with beta-
blockers resulted in modest reduction of 
cardiovascular diseases(strokes and heart 
attacks)and minimal or zero effects on 
mortality. These beta-blockers effects are 
inferior to those of other antihypertensive 
drugs. As noted that beta-blockers that 
was frequently studied in most 
randomized controlled trials were 
atenolol.29 Thus, to extrapolate these 
results to other agents in the beta-blocker 
class is unwarranted, because insufficient 
quantitave evidence (i.e outcomes data).30   
One class of beta-blockers that is 
still frequently used is bisoprolol. This 
agent has β1-blockade potency ratio ten-
fold higher than propranolol and moderate 
β1-selectivity. Bisoprolol also has zero 
intrinsic sympathomimetic activity, 
meaning that this agent will not slightly 
activate beta-receptor in addition to 
preventing the access of natural or 
synthetic catecholamines to the receptor, 
similar as seen in metoprolol or 
propanolol.27 As mentioned above, 
elevated heart rate as a sign of 
sympathetic overdrive is a common 
feature in patients with prehypertension 
and hypertension. One proposed 
mechanism to explain the 
antihypertensive actions of beta-blockers 
is its ability to have effects on 
prejunctional beta-receptors, resulting in 
reduction of norepinephrine release.27 In a 
study demonstrated by Julius et al, it 
showed that in the prehypertensive group, 
the heart rate remained higher than in the 
normotensive controls after the beta 
blockade using intravenous propranolol, 
but addition of parasympathetic blockade 
with atropine abolished its differences. 
This indicates that patients with 
prehypertension have an increased 
sympathetic and a decreased vagal tone.9   
Unlike thiazide diuretic or calcium 
channel blockers in which sympathetic 
activity does not entirely return to the 
treatment condition, beta-blocker may 
reduce sympathetic activity compared with 
the level measured in untreated patients 
and improve vagal cardiac control.31 In 
general, beta-blockers effects on 
adrenergic activity in essential 
hypertension may include lowering heart 
rate, reduce plasma norepinephrine and 
muscle sympathetic nerve traffic, and 
decrease plasma norepinephrine 
spillover.31 
 
Summary 
Hypertension is a condition 
characterized by hyperactivity of 
sympathetic nerve system. Cardiac 
sympathetic drive may trigger modification 
in functional and structural of myocardial, 
as well as increase stiffening of large 
blood vessels and generate 
atherosclerotic plaque, leading to greater 
morbidity and mortality. Beta-blockers is 
considered to reduce sympathetic nerve 
activity in patients with hypertension.  
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